Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Investigating the role of ficolin-2 in carotid stenosis and brain inflammation

Official title: Plaque and Brain Inflammation in Symptomatic Carotid Stenosis: Role of the Ficolin-2

Run by Hospices Civils de Lyon · NCT05850247 · Data updated 2026-11-12

This study is testing if a specific biomarker can help identify dangerous plaque in the carotid artery of patients who have had a mini-stroke or stroke, to see if they might benefit from a procedure to improve blood flow.

More Carotid Stenosis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorHospices Civils de Lyon
Academic / other
Locations1 site (Bron)
StatusRecruiting
StartedFebruary 13, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 6, 2025
Trial IDNCT05850247 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and over who have experienced a recent transient ischemic attack, retinal artery occlusion, or ischemic stroke and have significant carotid stenosis.

Probably not a fit

Patients with inflammatory or autoimmune diseases, active malignancies, or recent major surgeries may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to explore the relationship between plaque composition in carotid artery stenosis and the risk of ischemic stroke, focusing on the biomarker ficolin-2. It will involve patients who have experienced a transient ischemic attack, retinal artery occlusion, or ischemic stroke, and who have significant carotid stenosis. The study will utilize [18F]DPA-714 PET/MRI imaging to assess the state of the plaques and their inflammatory status. By identifying vulnerable plaques, the trial seeks to determine which patients may benefit from carotid revascularization.

Why it matters

Potential benefit: If successful, this study could lead to improved identification of patients at high risk for stroke, allowing for timely and targeted interventions.

How similar studies have gone: While the specific approach of using ficolin-2 as a biomarker in this context is novel, there is existing evidence supporting the role of the complement system in atherosclerosis.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients 18 years or over,
* Signed written informed consent before any study specific intervention,
* Probable ipsilateral transient ischemic attack (TIA - which involve a focal speech/language, motor or visual deficit referable to the distribution of a carotid artery and lasting less than 48 hours from the onset) OR retinal artery occlusion ≤ 48h OR ischemic stroke ≤ 48h from the onset,
* Atherosclerotic carotid stenosis between 50% and 99% (NASCET method), as confirmed by one of the imaging examinations (among: Doppler ultrasound, MR angiography, CT angiography, catheter angiography) performed after index TIA or ischemic stroke
* No other identified cause of TIA, ischemic stroke or retinal artery occlusion,

Exclusion Criteria:

* Patients with inflammatory or autoimmune disease, hepatocellular insufficiency, acute or chronic infection, active malignancy, myocardial infarction or major surgery within the previous 30 days of index hospitalization according to the investigator,
* Patients with severe renal insufficiency (estimated GFR \< 30 ml/min at inclusion or known dialysis),
* Patients with contraindication to MRI (agitation, claustrophobia, pacemaker, metallic (ferromagnetic) body, a known allergy to gadolinium) according to the investigator's judgment,
* Patients with modified Rankin score greater than 3,
* Patients currently enrolled in another clinical trial including investigational medicinal products,
* Female patient who is pregnant or lactating, or is of child-bearing and who did not agree to use highly effective methods of birth control throughout the study,
* Patient without health coverage,
* Patient under legal protection

Where it's running

  • Service de Neurologie vasculaire / CarMeN U1060 INSERM Hôpital Neurologique Pierre Wertheimer - GHE
    Bron, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.